Bristol Myers Squibb's ZENBEXUS Doubles MRD-Negative Response Rate…

Event summary

Bristol Myers Squibb presented Phase 3 EXCALIBER-RRMM trial results showing ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) achieved a 41.1% MRD-negative complete response rate vs. 20.7% for standard DVd treatment.
The trial, involving 420 evaluable patients with relapsed or refractory multiple myeloma, demonstrated a statistically significant improvement in MRD-negative CR rate (p<0.0001).
ZENBEXUS combination therapy received accelerated FDA approval on August 13, 2026, for patients with at least one prior line of therapy.
Safety profile showed manageable neutropenia with G-CSF support and lower rates of peripheral sensory neuropathy compared to DVd.

The big picture

Bristol Myers Squibb's positive Phase 3 results for ZENBEXUS represent a significant advancement in treating relapsed or refractory multiple myeloma, leveraging targeted protein degradation technology. The accelerated FDA approval underscores the potential of this novel therapeutic approach, which could reshape treatment paradigms in oncology. The company's ability to sustain this momentum will depend on further clinical validation and competitive differentiation in a rapidly evolving market.

What we're watching

Clinical Validation: Whether the MRD-negative response advantage of ZENBEXUS can translate into long-term progression-free survival benefits in the ongoing confirmatory analysis.
Market Positioning: How Bristol Myers Squibb positions ZENBEXUS against existing multiple myeloma treatments in a competitive oncology market.
Regulatory Pathway: The pace at which the FDA may require additional confirmatory data to maintain accelerated approval status.